HRP20170535T4 - Tehnike za predviđanje, otkrivanje i smanjenje nespecifičnog ometanja proteina u testovima koji uključuju imunoglobulinske jednostruke varijabilne domene - Google Patents
Tehnike za predviđanje, otkrivanje i smanjenje nespecifičnog ometanja proteina u testovima koji uključuju imunoglobulinske jednostruke varijabilne domene Download PDFInfo
- Publication number
- HRP20170535T4 HRP20170535T4 HRP20170535TT HRP20170535T HRP20170535T4 HR P20170535 T4 HRP20170535 T4 HR P20170535T4 HR P20170535T T HRP20170535T T HR P20170535TT HR P20170535 T HRP20170535 T HR P20170535T HR P20170535 T4 HRP20170535 T4 HR P20170535T4
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- polypeptide
- vhh
- isv
- sequence
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 27
- 108090000623 proteins and genes Proteins 0.000 title claims 27
- 108060003951 Immunoglobulin Proteins 0.000 title claims 2
- 102000018358 immunoglobulin Human genes 0.000 title claims 2
- 238000003556 assay Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 235000018102 proteins Nutrition 0.000 claims 26
- 102000007562 Serum Albumin Human genes 0.000 claims 10
- 108010071390 Serum Albumin Proteins 0.000 claims 10
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 210000004899 c-terminal region Anatomy 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (17)
1. Protein ili polipeptid za uporabu za liječenje, te navedeni protein ili polipeptid sadrži imunoglobulinsku jednostruku varijabilnu domenu (ISV) na njezinom C-terminalnom kraju, pri čemu navedena ISV je bilo VHH, sekvencno optimizirana VHH, humanizirana VHH ili kamelizirana VH, ili je ISV koja sadrži VH sekvencu različitu od VHH, sekvencno optimizirana VHH, humanizirana VHH ili kamelizirana VH ili koja je izvedena iz VH sekvence, koja ISV ima C-terminalni kraj sekvence VTVSS(X)n, gdje:
- n = 1, 2 ili 3 gdje je svaki X = Ala ili Gly; ili
- n = 1, 2 ili 3 gdje je svaki X = Ala; ili
- n = 1, 2 ili 3 gdje je svaki X = Gly; ili
- n = 2 ili 3 gdje je barem jedan X = Ala ili Gly; ili
- n = 2 ili 3 gdje svi osim jednog X = Ala ili Gly,
i koji protein ili polipeptid sadrži vezujući peptid serumskog albumina ili vezujuću domenu serumskog albumina i ima poluvijek izražen kao t1/2-beta kod ljudskog subjekta od barem 3 dana, pod uvjetom da navedeni protein ili polipeptid nije
[image]
ili
[image]
2. Protein ili polipeptid za uporabu prema zahtjevu 1, naznačen time da vezujući peptid serumskog albumina ili vezujuća domena serumskog albumina je vezujuća ISV serumskog albumina.
3. Protein ili polipeptid za uporabu prema zahtjevu 1, naznačen time da n = 1 ili n = 2.
4. Protein ili polipeptid za uporabu prema zahtjevu 1, naznačen time da n = 2 ili 3 i barem jedan X = Ala ili Gly ili n = 2 ili 3 i svi osim jednog X = Ala ili Gly, sa preostalim aminokiselinskim ostatkom X koji je neovisno odabran od bilo koje amino kiseline koja se javlja u prirodi.
5. Protein ili polipeptid za uporabu prema zahtjevu 4, naznačen time da je preostali aminokiselinski ostatak X neovisno odabran od Val, Leu i/ili Ile.
6. Protein ili polipeptid za uporabu prema zahtjevu 1, naznačen time da:
- n = 1, 2 ili 3 gdje je svaki X = Ala ili Gly; ili
- n = 1, 2 ili 3 gdje je svaki X = Ala; ili
- n = 1, 2 ili 3 gdje je svaki X = Gly.
7. Protein ili polipeptid za uporabu prema zahtjevu 1, naznačen time da X nije cistein.
8. Protein ili polipeptid za uporabu u terapiji koji navedeni protein ili polipeptid sadrži ISV na njegovom C-terminalnom kraju, naznačen time da je navedena ISV bilo VHH, sekvencno optimizirana VHH, humanizirana VHH ili kamelizirana VH, ili je ISV koja sadrži VH sekvencu različitu od VHH, sekvencno optimiziranu VHH, humaniziranu VHH ili kameliziranu VH ili koja je dobivena iz VH sekvence, koja ISV ima C-terminalni kraj sekvence VTVSS(X)n, u kojoj n je 1 do 5, kao što je 1, 2, 3, 4 ili 5, te u kojoj svaki X je aminokiselinski ostatak koji je neovisno odabran, pod uvjetom da X nije cistein, te koji protein ili polipeptid sadrži vezujući peptid serumskog albumina ili vezujuću domenu serumskog albumina i ima poluvijek izražen kao t1/2-beta kod ljudskog subjekta od barem 3 dana, pod uvjetom da navedeni protein ili polipeptid nije
[image]
ili
[image]
9. Protein ili polipeptid za uporabu prema zahtjevu 8, naznačen time da n je 1 ili 2.
10. Protein ili polipeptid za uporabu prema zahtjevu 8 ili 9, naznačen time da svaki X je amino kiselina koja se javlja u prirodi.
11. Protein ili polipeptid za uporabu prema bilo kojem od zahtjeva 8-10, naznačen time da je svaki X odabran iz skupine koju čine alanin (A), glicin (G), valin (V), leucin (L) ili izoleucin (I).
12. Protein ili polipeptid za uporabu prema bilo kojem od zahtjeva 1-11, naznačen time da navedeni C-terminalni kraj ISV je VHH, sekvencno optimizirana VHH, humanizirana VHH ili kamelizirana VH.
13. Protein ili polipeptid za uporabu prema zahtjevu 8, naznačen time da vezujući peptid serumskog albumina ili vezujuća domena serumskog albumina je vezujuća ISV serumskog albumina.
14. Farmaceutski pripravak za uporabu u terapiji, naznačen time da sadrži protein ili polipeptid prema bilo kojem od zahtjeva 1-13, te barem jedan prikladan nosač, razrjeđivač ili pomoćnu tvar.
15. Farmaceutski pripravak za uporabu u terapiji prema patentnom zahtjevu 14, naznačen time da:
- navedeni pripravak, protein ili polipeptid je namijenjen za liječenje kronične bolesti kod čovjeka, i/ili
- navedeni protein, polipeptid je namijenjen da bude prisutan u cirkulaciji subjekta kojemu se on daje tijekom perioda barem od jednog tjedna; i/ili
- navedeni protein, polipeptid je takav da ima poluvijek izražen kao t1/2-beta kod subjekta koji je čovjek od barem 3 dana; i/ili
- navedeni protein, polipeptid ili farmaceutski pripravak je namijenjen da se daje čovjeku kao dvije ili više doza koje se primjenjuju tijekom perioda od barem 3 dana.
16. Farmaceutski pripravak za uporabu u terapiji prema patentnom zahtjevu 15, naznačen time da navedeni protein, polipeptid je namijenjen da bude prisutan u cirkulaciji u farmakološki aktivnim razinama kod subjekta na kojeg se primjenjuje u terapijski aktivnoj dozi barem tijekom perioda od jednog tjedna.
17. Farmaceutski pripravak za uporabu u terapiji prema patentnom zahtjevu 15 ili 16, naznačen time da je navedeni protein, polipeptid ili farmaceutski pripravak namijenjen da se primjenjuje na ljudskom biću kao dvije ili više doza koje su kronično primjenjuju.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500360P | 2011-06-23 | 2011-06-23 | |
| US201161500464P | 2011-06-23 | 2011-06-23 | |
| US201161541368P | 2011-09-30 | 2011-09-30 | |
| PCT/EP2011/067132 WO2012042026A1 (en) | 2010-09-30 | 2011-09-30 | Biological materials related to c-met |
| US13/435,567 US8703135B2 (en) | 2010-09-30 | 2012-03-30 | Biological materials related to c-Met |
| PCT/EP2012/061304 WO2012175400A1 (en) | 2011-06-23 | 2012-06-14 | Serum albumin binding proteins |
| PCT/EP2012/062251 WO2012175741A2 (en) | 2011-06-23 | 2012-06-25 | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP12729968.3A EP2723769B2 (en) | 2011-06-23 | 2012-06-25 | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20170535T1 HRP20170535T1 (hr) | 2017-06-16 |
| HRP20170535T4 true HRP20170535T4 (hr) | 2022-08-19 |
Family
ID=46298413
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170535TT HRP20170535T4 (hr) | 2011-06-23 | 2012-06-25 | Tehnike za predviđanje, otkrivanje i smanjenje nespecifičnog ometanja proteina u testovima koji uključuju imunoglobulinske jednostruke varijabilne domene |
| HRP20192160TT HRP20192160T1 (hr) | 2011-06-23 | 2019-11-29 | Vezujući proteini serumskog albumina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192160TT HRP20192160T1 (hr) | 2011-06-23 | 2019-11-29 | Vezujući proteini serumskog albumina |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9573992B2 (hr) |
| EP (3) | EP4218933A1 (hr) |
| JP (3) | JP6324887B2 (hr) |
| CN (2) | CN106046168A (hr) |
| AU (1) | AU2012271974B2 (hr) |
| CA (1) | CA2839779C (hr) |
| CY (1) | CY1122691T1 (hr) |
| DK (1) | DK2723771T3 (hr) |
| ES (1) | ES2759936T3 (hr) |
| HR (2) | HRP20170535T4 (hr) |
| HU (1) | HUE047238T2 (hr) |
| IN (1) | IN2014CN00414A (hr) |
| LT (1) | LT2723771T (hr) |
| PL (1) | PL2723771T3 (hr) |
| PT (1) | PT2723771T (hr) |
| SI (1) | SI2723771T1 (hr) |
| WO (1) | WO2012175400A1 (hr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| BR122017005075B1 (pt) | 2011-06-23 | 2022-09-20 | Ablynx N.V | Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina |
| AU2012271974B2 (en) * | 2011-06-23 | 2017-01-12 | Ablynx Nv | Serum albumin binding proteins |
| JP6219287B2 (ja) * | 2011-09-30 | 2017-10-25 | アブリンクス エン．ヴェー． | ｃ−Ｍｅｔに関連する生物学的物質 |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| EP3982124A1 (en) | 2014-05-16 | 2022-04-13 | Ablynx NV | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
| DK3248986T3 (da) | 2014-05-16 | 2022-04-04 | Ablynx Nv | Variable immunoglobulindomæner |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| PL3233910T3 (pl) | 2014-12-19 | 2020-06-01 | Ablynx N.V. | Dimery nanociał połączone cysteiną |
| WO2016120843A1 (en) | 2015-01-29 | 2016-08-04 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| NO2768984T3 (hr) | 2015-11-12 | 2018-06-09 | ||
| JP7195142B2 (ja) | 2015-11-13 | 2022-12-23 | アブリンクス エン．ヴェー． | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン |
| JO3740B1 (ar) | 2015-11-18 | 2021-01-31 | Merck Sharp & Dohme | روابط pd1/ctla4 |
| EP3377531A2 (en) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| CN108473564B (zh) * | 2015-11-18 | 2022-04-08 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合剂 |
| MY189590A (en) | 2015-11-18 | 2022-02-18 | Merck Sharp & Dohme | Ctla4 binders |
| SG11201803976VA (en) * | 2015-11-27 | 2018-06-28 | Ablynx Nv | Polypeptides inhibiting cd40l |
| JP7101621B2 (ja) * | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| ES2926014T3 (es) | 2016-06-23 | 2022-10-21 | Ablynx Nv | Ensayos farmacocinéticos mejorados para dominios variables individuales de inmunoglobulina |
| WO2018091606A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| AU2017373746A1 (en) * | 2016-12-07 | 2019-05-30 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
| WO2018134235A1 (en) * | 2017-01-17 | 2018-07-26 | Ablynx Nv | Improved serum albumin binders |
| US11897944B2 (en) * | 2017-01-17 | 2024-02-13 | Ablynx N.V. | Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
| EP3602056A1 (en) | 2017-03-31 | 2020-02-05 | Ablynx N.V. | Improved immunogenicity assays |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CR20200196A (es) | 2017-10-13 | 2020-06-05 | Harpoon Therapeutics Inc | Proteínas trispecìficas y mètodos de uso |
| SG11202003341UA (en) | 2017-10-13 | 2020-05-28 | Harpoon Therapeutics Inc | B cell maturation antigen binding proteins |
| TW202000238A (zh) * | 2018-02-26 | 2020-01-01 | 比利時商艾伯林克斯公司 | 編碼肽連接子之經改良核苷酸序列 |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| CN110964107B (zh) * | 2018-09-30 | 2022-08-09 | 苏州康宁杰瑞生物科技有限公司 | Met结合分子、其组合和用途 |
| CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
| CN111138536B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗人血清白蛋白单域抗体的制备及其应用 |
| AU2020397210A1 (en) | 2019-12-06 | 2022-07-28 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting TNFa and OX40L |
| IL293561A (en) | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23 |
| KR20220123237A (ko) | 2019-12-09 | 2022-09-06 | 아블린쓰 엔.브이. | Il-13 및 tslp를 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩타이드 |
| CN110988361B (zh) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | 人血清白蛋白去除试剂盒 |
| JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス，インク． | Ｆｌｔ３結合タンパク質および使用方法 |
| BR112022018364A2 (pt) | 2020-03-30 | 2022-11-08 | Ablynx Nv | Método para produção e purificação de domínios variáveis únicos de imunoglobulina multivalente |
| EP4217390A1 (en) | 2020-09-25 | 2023-08-02 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| CN112142846B (zh) * | 2020-10-10 | 2022-07-08 | 西北大学 | Aox特异性抗体组合及其制备方法和用途 |
| CN115244076B (zh) | 2020-10-27 | 2023-08-04 | 北京质肽生物医药科技有限公司 | Gdf15融合蛋白及其用途 |
| KR20230123497A (ko) | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드 |
| WO2022129560A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| IL303740A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | Polypeptides that recruit T cells based on reactivity to alpha/beta receptors |
| WO2023284822A1 (en) * | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| TW202340240A (zh) * | 2021-11-17 | 2023-10-16 | 大陸商江蘇先聲藥業有限公司 | 多特異性抗體及其藥物用途 |
| WO2023111266A1 (en) | 2021-12-17 | 2023-06-22 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| WO2023134742A1 (zh) * | 2022-01-14 | 2023-07-20 | 浙江道尔生物科技有限公司 | 一种三靶点抗肿瘤药物、其制备方法及其应用 |
| US20240109965A1 (en) | 2022-06-14 | 2024-04-04 | Ablynx N.V. | Immunoglobulin single variable domains targeting t cell receptor |
| WO2023242371A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Ph-dependent hsa-binding molecules and methods of use |
| US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| DK1087013T3 (da) | 1992-08-21 | 2009-05-11 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
| EP0698097B1 (en) | 1993-04-29 | 2001-08-16 | Unilever N.V. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| NZ540771A (en) | 2003-01-10 | 2009-05-31 | Ablynx Nv | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
| CN104804095A (zh) * | 2004-08-05 | 2015-07-29 | 健泰科生物技术公司 | 人源化抗c-met 拮抗剂 |
| EP1888640B1 (en) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Improved nanobodies against tumor necrosis factor-alpha |
| US7875465B2 (en) | 2005-05-31 | 2011-01-25 | Canon Kabushiki Kaisha | Target substance capturing molecule |
| US7989219B2 (en) | 2005-05-31 | 2011-08-02 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
| EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
| CN101415730B (zh) * | 2006-03-30 | 2013-04-10 | 诺瓦提斯公司 | c-Met抗体的组合物和使用方法 |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| MX2009001293A (es) | 2006-08-03 | 2009-02-11 | Astrazeneca Ab | Anticuerpos dirigidos a (v(6 y usos de los mismos. |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CA2666511A1 (en) * | 2006-10-11 | 2008-04-17 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| KR20120125601A (ko) | 2007-05-24 | 2012-11-16 | 아블린쓰 엔.브이. | Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| EP2201040A1 (en) | 2007-09-24 | 2010-06-30 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
| US20110189203A1 (en) | 2007-11-27 | 2011-08-04 | Ablynx N.V. | Immunoglobulin constructs |
| EP2250201B1 (en) | 2008-01-29 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| EP2285833B1 (en) | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| SI2285408T1 (sl) | 2008-06-05 | 2019-02-28 | Ablynx N.V. | Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| US20110200525A1 (en) | 2008-10-09 | 2011-08-18 | Patz Jr Edward F | Vhh antibody fragments for use in the detection and treatment of cancer |
| RU2553214C2 (ru) | 2008-10-29 | 2015-06-10 | Аблинкс Н.В. | Способы очистки однодоменных антигенсвязывающих молекул |
| CN104127880A (zh) * | 2009-03-27 | 2014-11-05 | 葛兰素集团有限公司 | 药用融合体和缀合物 |
| WO2011064382A1 (en) | 2009-11-30 | 2011-06-03 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| EP2513147B1 (en) | 2009-12-18 | 2016-07-20 | Sanofi | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
| KR20130010114A (ko) | 2010-03-03 | 2013-01-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이파라토픽 ａ-베타 결합 폴리펩타이드 |
| EP2545077B1 (en) | 2010-03-10 | 2018-10-31 | Genmab A/S | Monoclonal antibodies against c-met |
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| AU2012271974B2 (en) * | 2011-06-23 | 2017-01-12 | Ablynx Nv | Serum albumin binding proteins |
| US20150344568A1 (en) | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| BR122017005075B1 (pt) | 2011-06-23 | 2022-09-20 | Ablynx N.V | Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina |
| JP6297976B2 (ja) | 2011-08-17 | 2018-03-20 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 改変タンパク質およびペプチド |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
-
2012
- 2012-06-14 AU AU2012271974A patent/AU2012271974B2/en active Active
- 2012-06-14 DK DK12727658T patent/DK2723771T3/da active
- 2012-06-14 EP EP23159592.7A patent/EP4218933A1/en active Pending
- 2012-06-14 PL PL12727658T patent/PL2723771T3/pl unknown
- 2012-06-14 CA CA2839779A patent/CA2839779C/en active Active
- 2012-06-14 LT LT12727658T patent/LT2723771T/lt unknown
- 2012-06-14 WO PCT/EP2012/061304 patent/WO2012175400A1/en active Application Filing
- 2012-06-14 EP EP18205150.8A patent/EP3466972A1/en active Pending
- 2012-06-14 HU HUE12727658A patent/HUE047238T2/hu unknown
- 2012-06-14 PT PT127276582T patent/PT2723771T/pt unknown
- 2012-06-14 EP EP12727658.2A patent/EP2723771B1/en active Active
- 2012-06-14 JP JP2014516279A patent/JP6324887B2/ja active Active
- 2012-06-14 CN CN201610392570.9A patent/CN106046168A/zh active Pending
- 2012-06-14 ES ES12727658T patent/ES2759936T3/es active Active
- 2012-06-14 SI SI201231696T patent/SI2723771T1/sl unknown
- 2012-06-14 US US14/128,719 patent/US9573992B2/en active Active
- 2012-06-14 IN IN414CHN2014 patent/IN2014CN00414A/en unknown
- 2012-06-14 CN CN201280030647.8A patent/CN103619878B/zh active Active
- 2012-06-25 HR HRP20170535TT patent/HRP20170535T4/hr unknown
-
2017
- 2017-01-03 US US15/397,313 patent/US20170210789A1/en not_active Abandoned
-
2018
- 2018-04-11 JP JP2018076201A patent/JP6843090B2/ja active Active
-
2019
- 2019-11-29 HR HRP20192160TT patent/HRP20192160T1/hr unknown
- 2019-12-10 CY CY20191101299T patent/CY1122691T1/el unknown
-
2021
- 2021-02-22 JP JP2021026177A patent/JP7304375B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012175400A1 (en) | 2012-12-27 |
| US20170210789A1 (en) | 2017-07-27 |
| CA2839779C (en) | 2020-10-06 |
| IN2014CN00414A (hr) | 2015-04-03 |
| PL2723771T3 (pl) | 2020-04-30 |
| CA2839779A1 (en) | 2012-12-27 |
| CN106046168A (zh) | 2016-10-26 |
| CN103619878B (zh) | 2016-10-26 |
| HUE047238T2 (hu) | 2020-04-28 |
| HRP20192160T1 (hr) | 2020-02-21 |
| CN103619878A (zh) | 2014-03-05 |
| EP2723771A1 (en) | 2014-04-30 |
| PT2723771T (pt) | 2019-12-11 |
| US9573992B2 (en) | 2017-02-21 |
| SI2723771T1 (sl) | 2019-12-31 |
| JP2018127478A (ja) | 2018-08-16 |
| LT2723771T (lt) | 2019-12-10 |
| ES2759936T3 (es) | 2020-05-12 |
| JP2014520129A (ja) | 2014-08-21 |
| EP2723771B1 (en) | 2019-09-11 |
| HRP20170535T1 (hr) | 2017-06-16 |
| EP4218933A1 (en) | 2023-08-02 |
| CY1122691T1 (el) | 2021-03-12 |
| AU2012271974A1 (en) | 2013-12-12 |
| AU2012271974B2 (en) | 2017-01-12 |
| DK2723771T3 (da) | 2019-12-02 |
| JP7304375B2 (ja) | 2023-07-06 |
| JP6843090B2 (ja) | 2021-03-17 |
| JP6324887B2 (ja) | 2018-05-16 |
| JP2021088585A (ja) | 2021-06-10 |
| US20140228546A1 (en) | 2014-08-14 |
| EP3466972A1 (en) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170535T4 (hr) | Tehnike za predviđanje, otkrivanje i smanjenje nespecifičnog ometanja proteina u testovima koji uključuju imunoglobulinske jednostruke varijabilne domene | |
| HRP20200503T1 (hr) | Fuzijski proteini | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| JP2018515088A5 (hr) | ||
| HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| HRP20201392T1 (hr) | Fgf21 fuzijski proteini dugotrajnog djelovanja i farmaceutski pripravci koji sadrže iste | |
| HRP20170905T1 (hr) | Antikancerogeni fuzijski protein | |
| RU2014102007A (ru) | Методы предсказания, обнаружения и уменьшения неспецифической интерференции белков в способах анализа с использованием одиночных вариабельных доменов иммуноглобулинов | |
| HRP20161614T1 (hr) | Terapijska sredstva za smanjenje razina paratiroidnog hormona | |
| JP2015120706A5 (hr) | ||
| WO2010111617A4 (en) | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | |
| HRP20151261T1 (hr) | Sastavi i postupci za lijeäśenje i dijagnosticiranje raka | |
| NZ601175A (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| RU2017103675A (ru) | Способ размещения в цитоплазме антител в виде полного иммуноглобулина путем проникновения антител через клеточную мембрану и его применение | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| HRP20191965T1 (hr) | Stabilizirani polipeptidi faktora rasta slični inzulinu | |
| RU2013106270A (ru) | Моноклональное антитело против addl и его применения | |
| JP2011523935A5 (hr) | ||
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| HRP20210635T1 (hr) | Novi mutant humanog seruma albumina | |
| JP2019514998A5 (hr) | ||
| SI2797950T1 (en) | Fusion protein against cancer | |
| RU2015105588A (ru) | Антитело, специфическое к cd22, и способы его применения |